AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10430734
Drug: Oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids prescribed for severe exacerbations
Trial: 7748095
Drug: Intra‐operative management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra‐operative management with endotracheal intubation, general anesthesia, nasogastric and urinary bladder catheters, position changes, rectal manometer, respiratory pressure module
Trial: 7748095
Drug: Measurement techniques
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measurement techniques (bladder, rectal, gastric)
Trial: 3579494
Drug: Scopolamine 0.25
RxNorm normalized name: scopolamine 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine 0.25 mg
Trial: 3579494
Drug: Scopolamine 0.1
RxNorm normalized name: scopolamine 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine 0.1 mg
Trial: 31808183
Drug: Treatment protocol
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment protocol from 2008-2011 (all foals with pulmonary abscesses treated)
Trial: 31808183
Drug: Treatment protocol
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment protocol from 2012-2016 (only foals with larger lesions treated)
Trial: 31808183
Drug: Treatment protocol
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment protocol from 2008-2011
Trial: 31808183
Drug: Treatment protocol
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment protocol from 2012-2016
Trial: 29288881
Drug: Daily screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily screening including confirmatory chart reviews
Trial: 16174597
Drug: Cefepime (Maxipime)
RxNorm normalized name: cefepime Injection [Maxipime]
DrugBank: Cefepime (DB01413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefepime (Maxipime) at 50 mg/kg intravenously twice daily
Trial: 16174597
Drug: Sulbactam/Cefoperazone (Sulperazone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulbactam/Cefoperazone (Sulperazone) at 50-100 mg/kg intravenously twice daily
Trial: 12045314
Drug: Psychoeducational multiple-family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational multiple-family group treatment
Trial: 9179369
Drug: Mistletoe lectin-I
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mistletoe lectin-I treatment
Trial: 3129318
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC), 25 mg/day
Trial: 3129318
Drug: Placebo, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 1 tablet/day
Trial: 11120961
Drug: Telithromycin 400
RxNorm normalized name: telithromycin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telithromycin 400 mg
Trial: 11120961
Drug: Telithromycin 800
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telithromycin 800 mg
Trial: 11120961
Drug: Telithromycin 1600
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telithromycin 1600 mg
Trial: 30994826
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical treatment
Trial: 31476881
Drug: IABP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IABP treatment
Trial: 25102384
Drug: Activity-based therapy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activity-based therapy (ABT) 9h/wk for 24 weeks
Trial: 12011136
Drug: Adjuvant oophorectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant oophorectomy and tamoxifen (20 mg orally every day for 5 years)
Trial: 10210974
Drug: HAART (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART (combination of zidovudine, lamivudine, and saquinavir)
Trial: 2575453
Drug: Dextropropoxyphene napsylate
RxNorm normalized name: Dextropropoxyphene napsylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextropropoxyphene napsylate with acetaminophen (DPN-A)
Trial: 57506
Drug: bromocriptine 2-5
RxNorm normalized name: bromocriptine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bromocriptine 2-5 mg twice daily from the 10th day of the menstrual cycle for 1-11 months
Trial: 57506
Drug: bromocriptine 2-5
RxNorm normalized name: bromocriptine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bromocriptine 2-5 mg twice daily for 186 cycles
Trial: 31557329
Drug: Waitlist/Treatment as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlist/Treatment as Usual (WL/TAU)
Trial: 28562434
Drug: 5-Fluorouracil and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-Fluorouracil and 5-Aminolevulinic Acid Photodynamic Therapy (5-FU-ALA-PDT)
Trial: 28562434
Drug: 5-Aminolevulinic Acid
RxNorm normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-Aminolevulinic Acid Photodynamic Therapy (ALA-PDT)
Trial: 23784895
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg herbal capsules twice daily
Trial: 23784895
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg placebo capsules twice daily
Trial: 19386210
Drug: Various treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatments used for EM (specific treatments not detailed in the abstract)
Trial: 16749914
Drug: Anastrozole 1
RxNorm normalized name: anastrozole 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole 1 mg daily for 3 months
Trial: 8872421
Drug: GHRH combined
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH combined with pyridostigmine (PD) (60 and 120 mg orally at -60 min)
Trial: 30414260
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 100 U/mL (Gla‐100)
Trial: 30278568
Drug: 5% lidocaine
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% lidocaine medicated patch (Lignopad)
Trial: 27075659
Drug: UCB-MNCs (4-μl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UCB-MNCs (4-μl injections, 1.6 million cells)
Trial: 27075659
Drug: UCB-MNCs (8-μl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UCB-MNCs (8-μl injections, 3.2 million cells)
Trial: 27075659
Drug: UCB-MNCs (16-μl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UCB-MNCs (16-μl injections, 6.4 million cells)
Trial: 27075659
Drug: UCB-MNCs (6.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UCB-MNCs (6.4 million cells) plus 30 mg/kg methylprednisolone (MP)
Trial: 27075659
Drug: UCB-MNCs (6.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UCB-MNCs (6.4 million cells) plus MP and a 6-week course of oral lithium carbonate (750 mg/day)
Trial: 9565250
Drug: Intravenous pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous pentoxifylline treatment (1.5 mg/kg/h)
Trial: 7800378
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (30 mg of beta-carotene, 1000 mg of ascorbic acid, and 800 IU of alpha-tocopherol per day for 9 months)
Trial: 3377462
Drug: Norfloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin (400 mg orally twice daily for 4 days)
Trial: 3377462
Drug: Theophylline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (200 mg of aminophylline three times daily for 4 days)
Trial: 31730832
Drug: COPD Assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COPD Assessment Test (CAT) administered before and after treatment of acute exacerbations
Trial: 28940638
Drug: l-citrulline (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-citrulline (6 g day-1)
Trial: 26342424
Drug: RTS,S/AS01 vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01 vaccination with booster dose
Trial: 17198101
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia with propofol and remifentanil; maintained constant rates to achieve BIS levels of 40-60 during the procedure
Trial: 11292410
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of 15 to 20 mg of crystalline triamcinolone acetonide at the end of surgery
Trial: 9380943
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (5 mg) via active matrix
Trial: 9380943
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (10 mg) via active matrix
Trial: 9380943
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (5 mg) via polyptychial matrix
Trial: 9380943
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (10 mg) via polyptychial matrix
Trial: 10932442
Drug: Standard hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard hospital treatment
Trial: 4758446
Drug: Frusemide 2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide 2000 mg daily
Trial: 31043522
Drug: Intranasal arginine
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal arginine vasopressin (AVP) treatment (24 IU for ages 6-9.5 years; 32 IU for ages 9.6-12.9 years)
Trial: 31043522
Drug: Intranasal arginine
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal arginine vasopressin (AVP) treatment
Trial: 25372313
Drug: 810-nm pulsed
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 810-nm pulsed diode laser treatment
Trial: 25372313
Drug: Overall score
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall score combining erythema and roughness/bumpiness for treatment
Trial: 23834688
Drug: Carvedilol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (up to 0.8 mg/kg/day)
Trial: 27444427
Drug: Group CBT
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group CBT (Cognitive Behavioral Therapy)
Trial: 19383032
Drug: Vildagliptin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin (50 mg b.i.d.)
Trial: 17274272
Drug: Electrolytic carbohydrate
RxNorm normalized name: CARBOHYDRATE/ELECTROLYTES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrolytic carbohydrate solution (group GP, n=14)
Trial: 29958055
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml normal saline (placebo)
Trial: 3060626
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil (CPDX‐PR) 400 mg daily for 7 days
Trial: 3060626
Drug: Cefaclor (CCL)
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefaclor (CCL) 750 mg daily for 7 days
Trial: 28910139
Drug: Family-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based cognitive-behavioral therapy (CBT), 10 sessions
Trial: 25940277
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus a decision aid presenting risks and benefits of different treatments (surgery and radiotherapy)
Trial: 24467988
Drug: Delayed antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed antibiotics (control group)
Trial: 15663405
Drug: Misoprostol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (400 mug oral + 400 mug intravaginal, repeated every 6 hours for a maximum of five doses)
Trial: 11961329
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml tap water with 1.0 mg F
Trial: 11961329
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml standard milk with 1.0 mg F
Trial: 11961329
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml standard milk
Trial: 11961329
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml F‐free tap water
Trial: 10874381
Drug: Regular intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular intramuscular (i.m.) injections of opioid analgesia
Trial: 8768863
Drug: Antithyroid drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithyroid drugs for 18 months
Trial: 8768863
Drug: Radioiodine (iodine-131)
RxNorm normalized name: Radioiodine
DrugBank: Iodide I-131 (DB09293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine (iodine-131) treatment
Trial: 6416664
Drug: Megavoltage irradiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megavoltage irradiation (general treatment)
Trial: 26464453
Drug: 0.06 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.06 mg/kg Sildenafil (Sild-L group)
Trial: 26464453
Drug: 0.6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/kg Sildenafil (Sild-H group)
Trial: 22847059
Drug: Rosiglitazone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (8 mg once daily for 6 weeks)
Trial: 19625385
Drug: D2‐like agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D2‐like agonist (Bromocriptine, 1.25 mg)
Trial: 19625385
Drug: D2‐like antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D2‐like antagonist (Sulpiride, 400 mg)
Trial: 10456967
Drug: Intradermal method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal method
Trial: 26223543
Drug: Adalimumab (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (24 mg/m², maximum dose 40 mg every other week)
Trial: 17407516
Drug: Dutasteride 0.5
RxNorm normalized name: dutasteride 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride 0.5 mg/day for 2 weeks before and after TURP, or 4 weeks before and 2 weeks after TURP
Trial: 15184247
Drug: Celecoxib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (100 or 400 mg twice daily)
Trial: 2109729
Drug: Terlipressin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin plus sublingual nitroglycerin (group I)
Trial: 19415122
Drug: WR279,396 applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WR279,396 applied twice a day for 20 days
Trial: 15543027
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy (combined with estrogen)
Trial: 8776361
Drug: Topical potent
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical potent glucocorticoid treatment (betamethasone-17-valerate) applied twice a day for 3 days
Trial: 27261995
Drug: Active group
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active group music therapy
Trial: 27261995
Drug: Receptive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receptive group music therapy
Trial: 12071338
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment in untreated type 1 patients
Trial: 12071338
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy adjustment in males aged 16-59 years
Trial: 12071338
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy in women with insufficient glucose control
Trial: 6620013
Drug: Chest physical
RxNorm normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chest physical therapy (CPT) administered by a parent, regular twice daily basis
Trial: 30526648
Drug: Buprenorphine 32
RxNorm normalized name: BUPRENORPHINE 32MG/0.64ML SA INJ SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 32 mg
Trial: 30526648
Drug: Buprenorphine 64
RxNorm normalized name: BUPRENORPHINE 64MG/0.18ML SA INJ SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 64 mg
Trial: 30526648
Drug: Buprenorphine 96
RxNorm normalized name: BUPRENORPHINE 96MG/0.27ML SA INJ SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 96 mg
Trial: 18372697
Drug: Nitroglycerin (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (0.3 mg sublingual administration)
Trial: 9702435
Drug: Orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 120 mg three times a day with a mildly hypocaloric diet
Trial: 31969443
Drug: Erector spinae
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erector spinae plane block (ESPB) with ropivacaine 0.5% and epinephrine (20 mL unilateral or 16 mL/side for bilateral)
Trial: 31969443
Drug: Paravertebral nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paravertebral nerve block (PVB) with ropivacaine 0.5% and epinephrine (20 mL unilateral or 16 mL/side for bilateral)
Trial: 31374368
Drug: 8-week home-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-week home-based physical activity intervention (twice weekly supervised resistance training and unsupervised walking program)
Trial: 20528005
Drug: Trans-resveratrol 2000
RxNorm normalized name: trans-resveratrol 3-β-glucoside
DrugBank: Polydatin (DB11263)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trans-resveratrol 2000 mg twice daily with standard breakfast
Trial: 20528005
Drug: Trans-resveratrol 2000
RxNorm normalized name: trans-resveratrol 3-β-glucoside
DrugBank: Polydatin (DB11263)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trans-resveratrol 2000 mg twice daily with high-fat breakfast
Trial: 20528005
Drug: Quercetin 500
RxNorm normalized name: quercetin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin 500 mg twice daily
Trial: 20528005
Drug: 5% alcohol
RxNorm normalized name: ALCOHOL 0.75 TOPICAL CLOTH [75% Alcohol Wipes]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% alcohol 100 mL
Trial: 20528005
Drug: Trans-resveratrol 2000
RxNorm normalized name: trans-resveratrol 3-β-glucoside
DrugBank: Polydatin (DB11263)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trans-resveratrol 2000 mg twice daily
Trial: 16156492
Drug: Common Factors
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common Factors Therapy (CFT)
Trial: 7772424
Drug: Ephedrine 0.6
RxNorm normalized name: pseudoephedrine 0.66 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 0.6 mg kg‐1 body weight
Trial: 2185693
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B syrup 2,400 mg/day
Trial: 2185693
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B syrup 1,200 mg/day
Trial: 2185693
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B syrup 800 mg/day
Trial: 2185693
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B syrup 400 mg/day
Trial: 7444371
Drug: Hog mucosa
RxNorm normalized name: hog epithelia extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hog mucosa heparin
Trial: 26795764
Drug: Waiting list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list group receiving conventional orthopaedic therapy (n=42)
Trial: 20671098
Drug: 10 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 weeks of drug therapy combined with behavioral intervention (pelvic‐floor muscle exercises, UI prevention strategies, delayed voiding)
Trial: 20671098
Drug: 10 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 weeks of drug therapy combined with behavioral intervention
Trial: 20671098
Drug: 10 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 weeks of drug therapy only
Trial: 18313371
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg zopiclone (test)